United States - English - NLM (National Library of Medicine)

curium us llc - thallous chloride tl-201 (unii: 3i8y076a0e) (thallous cation tl-201 - unii:4877x14g4c) - thallous cation tl-201 1 mci in 1 ml - thallous chloride tl 201 injection is a diagnostic radiopharmaceutical indicated for - myocardial perfusion imaging with planar scintigraphy or single-photon emission computed tomography (spect)  for the diagnosis of coronary artery disease by localization of: non-reversible defects (myocardial infarction) which may have prognostic value regarding survival. reversible defects (myocardial ischemia) when used in conjunction with exercise or pharmacologic stress. - non-reversible defects (myocardial infarction) which may have prognostic value regarding survival. - reversible defects (myocardial ischemia) when used in conjunction with exercise or pharmacologic stress. - localization of sites of parathyroid hyperactivity pre- and post-operatively in patients with elevated serum calcium and parathyroid hormone levels. none.  there are no adequate or well-controlled studies of thallous chloride tl 201 injection use in pregnant women. studies using human placentas demonstrate that thallous chloride tl 201 crosses t

United States - English - NLM (National Library of Medicine)

cardinal health 414, llc - technetium tc-99m tilmanocept (unii: 8ihi69pqtc) (technetium tc-99m tilmanocept - unii:8ihi69pqtc) - tilmanocept 250 ug - lymphoseek is a radioactive diagnostic agent indicated with or without scintigraphic imaging for: none. there are no available data on lymphoseek use in pregnant women. additionally, animal reproduction studies have not been conducted with technetium tc 99m tilmanocept. however, all radiopharmaceuticals, including lymphoseek, have a potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. if considering lymphoseek administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from the drug and the gestational timing of exposure. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies are 2 to 4% and 15

Canada - English - Health Canada

liebel-flarsheim company llc - ioversol - solution - 68% - ioversol 68% - roentgenography

Canada - English - Health Canada

liebel-flarsheim company llc - ioversol - solution - 74% - ioversol 74% - roentgenography

Canada - English - Health Canada

liebel-flarsheim company llc - ioversol - solution - 51% - ioversol 51% - roentgenography

Canada - English - Health Canada

liebel-flarsheim company llc - ioversol - solution - 74% - ioversol 74% - roentgenography

Canada - English - Health Canada

liebel-flarsheim company llc - ioversol - solution - 51% - ioversol 51% - roentgenography

Canada - English - Health Canada

liebel-flarsheim company llc - ioversol - solution - 64% - ioversol 64% - roentgenography

Canada - English - Health Canada

liebel-flarsheim company llc - ioversol - solution - 68% - ioversol 68% - roentgenography

Canada - English - Health Canada

liebel-flarsheim company llc - ioversol - solution - 64% - ioversol 64% - roentgenography